Arvinas, a clinical-stage biotechnology firm, is pioneering the development of therapies that degrade disease-causing proteins. The company has engineered proteolysis targeting chimeras (PROTAC) targeted protein degraders that capitalize on the body's natural protein disposal system to break down and remove harmful proteins. Among Arvinas' promising product pipeline are the investigational orally bioavailable PROTAC protein degraders Bavdegalutamide and ARV-766, which are in Phase 1/2 clinical trials for the treatment of men with metastatic castration-resistant prostate cancer. The company's ARV-471 also shows potential as an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for treating patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is currently in Phase 3 clinical trial. Arvinas has garnered partnerships with industry heavyweights Pfizer, Genentech, Roche, and Bayer. Founded in 2013, Arvinas calls New Haven, Connecticut, home.
Arvinas's ticker is ARVN
The company's shares trade on the NASDAQ stock exchange
They are based in New Haven, Connecticut
There are 201-500 employees working at Arvinas
Arvinas is in the Healthcare sector
Arvinas is in the Biotechnology industry
The following five companies are Arvinas's industry peers: